Desuden var forekomsten af krampeanfald hos patienterne i fase 1- 4- forsøg højere i DepoCyte - gruppen (7/ 33, 21%) end i cytarabin- gruppen (1/ 28, 4%).
In addition, in Phase 1-4 studies, the patient incidence of convulsions was higher in the DepoCyte group (7/ 33, 21%) than in the cytarabine group (1/ 28, 4%).